There is no consensus agreement regarding optimal management of locally excised ductal carcinoma in situ ... with micropapillary DCIS and only 7.3% of those with predominantly cribriform DCIS.

The finding has implications for breast cancer treatment and for research aimed at identifying biomarkers for recurrence, she said. In about a fourth of cases, patients with DCIS have recurrences ...

More information: Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ A Secondary Analysis of the COMET Randomized Clinical Trial, JAMA Oncology (2024). DOI: 10.1001/jamaoncol.2024.6556 ...

After two years, nearly 9% of the women who'd gotten surgery went on to develop cancer in the breast where the DCIS was first found, compared with 3% in the watch-and-wait group, results show.

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront ...

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast ...

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast ...